Please log in to view this page
Username
Password
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...
